Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Simple item page
dc.contributor.authorKahraman S.
dc.contributor.authorErul E.
dc.contributor.authorSeyyar M.
dc.contributor.authorGumusay O.
dc.contributor.authorBayram E.
dc.contributor.authorDemirel B.C.
dc.contributor.authorAcar O.
dc.contributor.authorAksoy S.
dc.contributor.authorBaytemur N.K.
dc.contributor.authorSahin E.
dc.contributor.authorCabuk D.
dc.contributor.authorBasaran G.
dc.contributor.authorPaydas S.
dc.contributor.authorYaren A.
dc.contributor.authorGuven D.C.
dc.contributor.authorErdogan A.P.
dc.contributor.authorDemirci U.
dc.contributor.authorYasar A.
dc.contributor.authorBayoglu İ.V.
dc.contributor.authorHizal M.
dc.contributor.authorGulbagci B.
dc.contributor.authorPaksoy N.
dc.contributor.authorDavarci S.E.
dc.contributor.authorYilmaz F.
dc.contributor.authorDogan O.
dc.contributor.authorOrhan S.O.
dc.contributor.authorKayikcioglu E.
dc.contributor.authorAytac A.
dc.contributor.authorKeskinkilic M.
dc.contributor.authorMocan E.E.
dc.contributor.authorUnal O.U.
dc.contributor.authorAydin E.
dc.contributor.authorYucel H.
dc.contributor.authorIsik D.
dc.contributor.authorEren O.
dc.contributor.authorUluc B.O.
dc.contributor.authorOzcelik M.
dc.contributor.authorHacibekiroglu I.
dc.contributor.authorAydiner A.
dc.contributor.authorDemir H.
dc.contributor.authorOksuzoglu B.
dc.contributor.authorCilbir E.
dc.contributor.authorCubukcu E.
dc.contributor.authorCetin B.
dc.contributor.authorOktay E.
dc.contributor.authorErol C.
dc.contributor.authorOkutur S.K.
dc.contributor.authorYildirim N.
dc.contributor.authorAlkan A.
dc.contributor.authorSelcukbiricik F.
dc.contributor.authorAksoy A.
dc.contributor.authorKarakas Y.
dc.contributor.authorOzkanli G.
dc.contributor.authorDuman B.B.
dc.contributor.authorAydin D.
dc.contributor.authorDulgar O.
dc.contributor.authorEr M.M.
dc.contributor.authorTeker F.
dc.contributor.authorYavuzsen T.
dc.contributor.authorAykan M.B.
dc.contributor.authorInal A.
dc.contributor.authorIriagac Y.
dc.contributor.authorKalkan N.O.
dc.contributor.authorKeser M.
dc.contributor.authorSakalar T.
dc.contributor.authorMenekse S.
dc.contributor.authorKut E.
dc.contributor.authorBilgin B.
dc.contributor.authorKaraoglanoglu M.
dc.contributor.authorSunar V.
dc.contributor.authorOzdemir O.
dc.contributor.authorTurhal N.S.
dc.contributor.authorKaradurmus N.
dc.contributor.authorYalcin B.
dc.contributor.authorNahit Sendur M.A.
dc.date.accessioned2025-04-10T11:03:40Z
dc.date.available2025-04-10T11:03:40Z
dc.date.issued2023
dc.description.abstractBackground: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. © 2023 Future Medicine Ltd.
dc.identifier.DOI-ID10.2217/fon-2022-1287
dc.identifier.urihttp://hdl.handle.net/20.500.14701/44882
dc.publisherNewlands Press Ltd
dc.titleTreatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu